Health Systems Product News
Sumatriptan Succinate Injection
Sandoz (Princeton, NJ) recently introduced SumatriptanSuccinate Injection.The product is the generic equivalentof GlaxoSmithKline?sImitrex. Sumatriptan SuccinateInjection is indicated for the acute treatment of migraineheadaches with or without aura and the acute treatment of cluster headache episodes. The product is not for use inthe management of hemiplegic or basilar headache. Themaximum single recommended adult dose of SumatriptanSuccinate Injection is 6 mg injected subcutaneously. Themaximum recommended dose that may be given in 24hours is two 6-mg injections separated by at least 1 hour.Each 0.5 mL of Sumatriptan Succinate Injection 12-mg/mL solution contains 6 mg of sumatriptan (base) as thesuccinate salt and is supplied as a clear, colorless to paleyellow, sterile, nonpyrogenic solution in the followingpacks: two 6-mg single-dose prefilled syringe cartridgeswith a patient information leaflet with instructions for useand a single-dose vial in cartons containing 5 vials. Formore information, visit www.us.sandoz.com.
Nexterone (amiodarone HCl) Injection
Prism Pharmaceuticals Inc (King of Prussia, PA) recentlyreceived FDA approval for its new drug application forNexterone. The product is an antiarrhythmic agent indicatedfor initiation of treatment and prophylaxis of frequentlyrecurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patientsrefractory to other therapy. Nexterone also can be usedto treat patients with VT/VF for whom oral amiodarone isindicated, but who are unable to take oral medication. Therecommended starting dose of Nexterone is about 1000mg over the first 24 hours of therapy. Nexterone is availablein single-use glass vials packaged in individual cartonsof 150 mg/3 mL in a 5-mL vial, 450 mg/9 mL in a 10-mLvial, and 900 mg/18 mL in a 20-mL vial. The product alsois available in single-use glass prefilled syringes packagedin blister packs of 150 mg/3 mL in a 5-mL prefilled syringe.For more information, visit www.prismpharma.com.
